

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/517,214	Art Unit:	Tba
Filed:	11/23/2004	Examiner:	tba
1 <sup>st</sup> Inventor:	MAEKAWA, T.	Allowed:	
For:	1,2-Azole Derivatives with Hypoglycemic And Hypolipidemic Activity		
Atty. Dkt. No.	3065 USOP	Paper No.:	

**Notice to Comply with Sequence Listing Requirements**

**MAIL STOP SEQUENCE**

Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

Sir:

In reply to the Notice mailed 12/13/2005, Applicants respectfully submit a substitute written Sequence Listing for the Specification and a DOS Text CRF Sequence Listing file "3065 USOP SEQ V2.txt" on the enclosed 3.5" IBM PC/AT computer disk, with a copy of the notice.


Please substitute the Written Sequence Listing for the Sequence Listing filed with the original PCT application.

The undersigned hereby certifies that the CRF and the written Sequence Listing are the same in content. The Sequence Listing contains no new matter.

Respectfully submitted,

Dated: December 20, 2005

(847)383-3372  
(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA